Durable Control of Mycosis Fungoides after Sepsis: “Coley's Toxin?” Case Report and Review of the Literature
暂无分享,去创建一个
[1] J. Scarisbrick,et al. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] S. Horwitz,et al. Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? , 2017, Expert review of hematology.
[3] Ash A. Alizadeh,et al. Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study , 2016 .
[4] M. Millenson,et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Pileri,et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] M. Weinstock,et al. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. , 2007, Archives of dermatology.
[7] R. Kurzrock,et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. , 2006, Clinical lymphoma & myeloma.
[8] M. Offidani,et al. Long‐term experience with low‐dose interferon‐α and PUVA in the management of early mycosis fungoides , 2005, European journal of haematology.
[9] M. Girardi,et al. Mycosis Fungoides and Sezary Syndrome. , 2017, Hematology/oncology clinics of North America.
[10] David A Jones,et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. , 2003, Blood.
[11] S. H. Hoption Cann,et al. Dr William Coley and tumour regression: a place in history or in the future. , 2003, Postgraduate medical journal.
[12] S. A. Cann,et al. Dr William Coley and tumour regression: a place in history or in the future , 2003 .
[13] A. Varghese,et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.
[14] S. Pileri,et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] V. Heinemann,et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.
[16] P. Mazza,et al. Is interferon alpha in cutaneous T‐cell lymphoma a treatment of choice? , 1991, British journal of haematology.